Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: International Dermatology Outcome Measures (IDEOM) is a non-profit organization whose mission is to improve the availability of evidence-based, consensus-driven outcome measures for dermatological diseases. IDEOM facilitates collaboration between stakeholders from various backgrounds, including researchers, patients, physicians, and industry representatives, to develop objective benchmark metrics that enable better treatment and management of dermatologic conditions.
Summary: The 2023 IDEOM Annual Meeting was held June 23-24, 2023. Workgroups in psoriatic disease, hidradenitis suppurativa, geriatric dermatology, connective tissue disease, vitiligo, itch, actinic keratosis, acne, and cutaneous T-cell lymphoma discussed the progress of their respective outcome-measures research. This report summarizes each workgroup’s updates since the 2022 annual meeting and their next steps as established during the 2023 IDEOM Annual Meeting. J Drugs Dermatol. 2024;23(12):1114-1120. doi:10.36849/JDD.8363.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.36849/jdd.8363 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Advances, challenges, and future directions in trauma-related Findable, Accessible, Interoperable, Reusable (FAIR) data efforts.
J Trauma Stress
September 2025
Center of Alcohol and Substance Use Studies, Graduate School of Applied and Professional Psychology, Rutgers University-New Brunswick, Piscataway, New Jersey, USA.
Findable, Accessible, Interoperable, and Reusable (FAIR) data advances are becoming more common and more important across research fields given the large amount of research data in need of synthesis and application. Many novel methods improve the efficiency and accuracy of data reuse, combination, and synthesis, which is necessary given that there are over 500 published randomized controlled trials of posttraumatic stress disorder treatments in adults; however, these methods are still relatively new to the field of traumatic stress research. We provide a brief overview of relevant FAIR data efforts from other fields and within trauma health care and research; share examples of trauma-related FAIR data efforts to demonstrate recent advances and challenges; and suggest potential next steps to continue making trauma data more FAIR.
View Article and Find Full Text PDF---Pars plana vitrectomy in congenital X-linked retinoschisis: a scoping review.
Graefes Arch Clin Exp Ophthalmol
September 2025
Department of Ophthalmology, Emory University School of Medicine, 1365B Clifton Road, NE, Suite 2400, Atlanta, GA, 30322, USA.
Purpose: Congenital X-linked retinoschisis (XLRS) has limited treatment options. Gene augmentation via pars plana vitrectomy (PPV) and subretinal RS1 gene delivery is promising, yet it is unclear how PPV may impact outcomes. We explored literature to better understand PPV outcomes in XLRS.
View Article and Find Full Text PDF2025 Annual Meeting American College of Clinical Pharmacology®.
Clin Pharmacol Drug Dev
September 2025
Towards causal inference-based antidepressant selection with brain and blood biomarkers.
Neuropsychopharmacology
September 2025
Center for Depression Research and Clinical Care, Peter O'Donnell Jr. Brain Institute and the Department of Psychiatry, University of Texas Southwestern Medical Center, Dallas, TX, USA.
This report sought to employ multi-modal integration of pre-treatment brain (electroencephalogram, resting-state functional magnetic resonance imaging) and blood (immune and metabolic) biomarkers to facilitate causal inference-based treatment selection by virtue of establishing predictability of remission to multi-stage antidepressant treatment. Data from two stages of pharmacotherapy in the 'Establishing Moderators and Biosignatures of Antidepressant Response for Clinical Care for Depression' (EMBARC) study from participants with both brain and blood biomarkers were included (N = 197). Participants were initially randomized to sertraline or placebo (Stage 1), and depending on clinical response at week-8, their therapy in Stage 2 was either maintained or switched (to sertraline, if a non-responder to placebo, or to bupropion, if a non-responder to sertraline).
View Article and Find Full Text PDF